Ascendis Pharma A/S SEC filings ASND
Ascendis Pharma A/S has 795 filings in SEC EDGAR's recent list, going back to Aug 1, 2014. Its latest annual report, Form 20-F, was filed on Feb 11, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 26, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SD | Specialized disclosure (conflict minerals) | May 22, 2026 | — |
| 8-A12B/A | Filing | Apr 20, 2026 | — |
| SD | Specialized disclosure (conflict minerals) | May 14, 2025 | — |
| SD | Specialized disclosure (conflict minerals) | May 29, 2024 | — |
| SD | Specialized disclosure (conflict minerals) | May 30, 2023 | — |
| SD | Specialized disclosure (conflict minerals) | May 26, 2022 | — |
| CT ORDER | Filing | Jul 15, 2020 | — |
| CT ORDER | Filing | Feb 22, 2019 | — |
| CT ORDER | Filing | May 3, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2018 | — |
| CORRESP | Letter to the SEC | Feb 1, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2018 | — |
| CORRESP | Letter to the SEC | Dec 20, 2017 | — |
| CORRESP | Letter to the SEC | Nov 29, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2017 | — |
| CORRESP | Letter to the SEC | Oct 25, 2017 | — |
| CORRESP | Letter to the SEC | Oct 10, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2017 | — |
| CT ORDER | Filing | Jul 19, 2017 | — |
| EFFECT | Filing | Apr 5, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2017 | — |
| CORRESP | Letter to the SEC | Apr 3, 2017 | — |
| EFFECT | Filing | Jun 2, 2016 | — |
| CORRESP | Letter to the SEC | May 31, 2016 | — |
| UPLOAD | Letter from the SEC | May 27, 2016 | — |
| EFFECT | Filing | Feb 17, 2016 | — |
| CORRESP | Letter to the SEC | Feb 12, 2016 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2016 | — |
| CT ORDER | Filing | Jan 30, 2015 | — |
| EFFECT | Filing | Jan 27, 2015 | — |
| EFFECT | Filing | Jan 27, 2015 | — |
| CORRESP | Letter to the SEC | Jan 26, 2015 | — |
| CORRESP | Letter to the SEC | Jan 26, 2015 | — |
| CERTNAS | Auto-generated paper document | Jan 26, 2015 | — |
| 8-A12B | Filing | Jan 26, 2015 | — |
| CORRESP | Letter to the SEC | Jan 16, 2015 | — |
| CORRESP | Letter to the SEC | Jan 9, 2015 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2015 | — |
| D | Filing | Dec 9, 2014 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2014 | — |
| DRSLTR | Filing | Oct 20, 2014 | — |
| DRS/A | Filing | Oct 20, 2014 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2014 | — |
| DRSLTR | Filing | Sep 9, 2014 | — |
| DRS/A | Filing | Sep 9, 2014 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2014 | — |
| DRS | Filing | Aug 1, 2014 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ASND (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Denmark
- Headquarters
- Hellerup
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1612042
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.